Understanding how sugar molecules on antibodies relate to Alzheimer's Disease
Official title: Deciphering the IgG glycosylation code of Alzheimer's Disease
Funded at Emory University · NIH-11014374 · Data updated 2026-11-12
This study is looking at how sugar molecules attached to antibodies might affect the immune system in people with Alzheimer's Disease, hoping to find clues that could lead to better treatments and ways to track the disease's progress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $492,802 |
| NIH project number | 5R01AG085587-02 |
| Project ID | NIH-11014374 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease, particularly those in the early to moderate stages.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research investigates the role of glycosylation, the process of adding sugar molecules to antibodies, in the context of Alzheimer's Disease. By analyzing how different glycoforms of IgG antibodies interact with immune receptors, the study aims to uncover their potential impact on the immune response in Alzheimer's patients. The researchers will utilize advanced techniques to assess the glycosylation patterns of antibodies over time, correlating these patterns with disease progression and severity. This approach may help identify biomarkers for Alzheimer's and improve therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new diagnostic tools and treatments that enhance the immune response in Alzheimer's Disease.
How similar studies have gone: Previous research has shown promising results in understanding antibody glycosylation in other diseases, suggesting potential for success in this novel approach for Alzheimer's.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Sundberg, Eric John — Emory University
- Study coordinator: Sundberg, Eric John
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.